Stock Research for TROV

TROV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TROV Stock Chart & Research Data

The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TROV Due diligence Resources & Stock Charts

The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TROV Detailed Price Forecast - CNN Money CNN View TROV Detailed Summary - Google Finance
Yahoo View TROV Detailed Summary - Yahoo! Finance Zacks View TROV Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View TROV Trends & Analysis - Trade-Ideas Barrons View TROV Major Holders - Barrons
NASDAQ View TROV Call Transcripts - NASDAQ Seeking View TROV Breaking News & Analysis - Seeking Alpha
Spotlight View TROV Annual Report - CompanySpotlight.com OTC Report View TROV OTC Short Report - OTCShortReport.com
TradeKing View TROV Fundamentals - TradeKing Charts View TROV SEC Filings - Bar Chart
WSJ View Historical Prices for TROV - The WSJ Morningstar View Performance/Total Return for TROV - Morningstar
MarketWatch View the Analyst Estimates for TROV - MarketWatch CNBC View the Earnings History for TROV - CNBC
StockMarketWatch View the TROV Earnings - StockMarketWatch MacroAxis View TROV Buy or Sell Recommendations - MacroAxis
Bullish View the TROV Bullish Patterns - American Bulls Short Pains View TROV Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View TROV Stock Mentions - StockTwits PennyStocks View TROV Stock Mentions - PennyStockTweets
Twitter View TROV Stock Mentions - Twitter Invest Hub View TROV Investment Forum News - Investor Hub
Yahoo View TROV Stock Mentions - Yahoo! Message Board Seeking Alpha View TROV Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for TROV - SECform4.com Insider Cow View Insider Transactions for TROV - Insider Cow
CNBC View TROV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TROV - OTC Markets
Yahoo View Insider Transactions for TROV - Yahoo! Finance NASDAQ View Institutional Holdings for TROV - NASDAQ


Stock Charts

FinViz View TROV Stock Insight & Charts - FinViz.com StockCharts View TROV Investment Charts - StockCharts.com
BarChart View TROV Stock Overview & Charts - BarChart Trading View View TROV User Generated Charts - Trading View




Latest Financial News for TROV


Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib
Posted on Tuesday December 11, 2018

As a result, new therapies are being developed in an effort to bring improved treatment options to patients, especially for some of the toughest-to-treat cancers. Trovagene caught my attention after the company released data from a Phase 1b/2 clinical trial of Onvansertib for the treatment of patients with Acute Myeloid Leukemia (AML). Through the ongoing Phase 1b segment of the trial, the company is working to identify the maximum-tolerated dose of Onvansertib in patients with AML who are ineligible for induction therapy or who have relapsed or refractory disease.


New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML
Posted on Monday December 03, 2018

SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today presented updated data from its ongoing Phase 1b/2 study evaluating Onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML). The data, featured in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting, demonstrate that Onvansertib, in combination with LDAC or decitabine, even at the dose-escalation phase of the trial, is benefiting patients who have relapsed/refractory Acute Myeloid Leukemia (AML), and that the combination regimen is safe and well-tolerated, with no serious adverse events (SAEs) reported to-date.


What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?
Posted on Wednesday November 21, 2018

TrovaGene Inc (NASDAQ:TROV), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is TROV will


Trovagene, Inc. Receives Positive Nasdaq Listing Decision
Posted on Thursday November 15, 2018

SAN DIEGO, Nov. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 bid price requirement. "I am pleased that the Nasdaq Hearing Panel responded favorably," said Dr. Thomas Adams, Executive Chairman of Trovagene.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.